TY - JOUR T1 - When Can Elimination of SARS-CoV-2 Infection be Assumed? Simulation Modelling in a Case Study Island Nation JF - medRxiv DO - 10.1101/2020.05.16.20104240 SP - 2020.05.16.20104240 AU - Nick Wilson AU - Matthew Parry AU - Ayesha J Verrall AU - Michael G Baker AU - Markus Schwehm AU - Martin Eichner Y1 - 2020/01/01 UR - http://medrxiv.org/content/early/2020/05/20/2020.05.16.20104240.abstract N2 - Aims We aimed to determine the length of time from the last detected case of SARS-CoV-2 infection before elimination can be assumed at a country level in an island nation.Methods A stochastic version of the SEIR model Covid SIM v1.1 designed specifically for COVID-19 was utilised. It was populated with data for the case study island nation of New Zealand (NZ) along with relevant parameters sourced from the NZ and international literature. This included a testing level for symptomatic cases of 7,800 tests per million people per week.Results It was estimated to take between 27 and 33 days of no new detected cases for there to be a 95% probability of epidemic extinction. This was for effective reproduction numbers (Re) in the range of 0.50 to 1.0, which encompass such controls as case isolation (the shorter durations relate to low Re values). For a 99% probability of epidemic extinction, the equivalent time period was 37 to 44 days. In scenarios with lower levels of symptomatic cases seeking medical attention and lower levels of testing, the time period was up to 53 to 91 days (95% level).Conclusions In the context of a high level of testing, a period of around one month of no new notified cases of COVID-19 would give 95% certainty that elimination of SARS-CoV-2 transmission had been achieved.Competing Interest StatementThe authors have declared no competing interest.Funding StatementDr Schwehm is supported by the University of Tübingen and the IMAAC-NEXT Association. Professor Wilson is supported by the New Zealand Health Research Council and Ministry of Business Innovation and Employment (MBIE) funding of the BODE3 Programme.Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll the Excel files with the results are available from the authors on request ER -